Treatment guidelines for adults with active non-radiographic axial spondyloarthritis recommend the use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Tumor Necrosis Factor-alpha (TNF-alpha) inhibitors. If these first-line treatments don’t work or aren’t suitable, doctors may consider secukinumab or ixekizumab (IL-17 inhibitors). Clinical trials show that upadacitinib, an oral Janus Kinase (JAK) inhibitor, can reduce symptoms and improve the quality of life in Spondyloarthritis (SpA) patients. This effectiveness rivals that of biologics. Clinicians use the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score and/or Visual Analogue Scale (VAS) score to measure this. A cost comparison shows that upadacitinib costs about the same and provides similar health benefits as secukinumab and ixekizumab.
The update suggests considering upadacitinib as an alternative to the National Institute for Health and Care Excellence (NICE) recommended Interleukin (IL)-17 inhibitors. This is especially important if conventional therapy doesn’t control the condition well enough or if TNF-alpha inhibitors aren’t suitable or effective.
Clinical and patient experts highlighted the convenience of upadacitinib over IL-17 inhibitors owing to its oral administration.
📊 The burden of hearing loss in Africa is rising, with projections estimating that 54 million people will be affected by 2030 if no action is taken. This alarming increase highlights the urgent need for policy advocacy and improved access to ear and hearing care services.
Discover the key findings from the WHO report and the steps needed to address this pressing issue.
#SyenzaNews #HearingHealth #PublicHealth
📊 Turkey’s pharmaceutical sector is on the rise! The latest “August 2024 Foreign Trade Analysis” offers a deep dive into the performance and dynamics of foreign trade, showcasing a 3.5% increase in total exports. 🌍 Discover the insights and market trends shaping the future of the pharmaceutical industry in Türkiye.
#SyenzaNews #PharmaceuticalIndustry #TradeAnalysis #Türkiye
🌍 Celebrating a decade of **ethical collaboration** among healthcare leaders! Health Policy Watch explores the groundbreaking achievements and future directions of this international consensus. By uniting efforts, we can tackle complex health challenges more effectively.
Read more about the role of ethical collaboration in shaping global health outcomes!
#SyenzaNews #GlobalHealth #EthicalCollaboration
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
